This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Beijing Hanmi Pharmaceutical Co., Ltd.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Jiangcheng Xu: Innovator in IRAK4 Inhibition
Introduction
Jiangcheng Xu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit IRAK4 kinase activity. His work is crucial for advancing treatments for various diseases.
Latest Patents
Jiangcheng Xu holds a patent for an IRAK4 inhibitor and its use. The patent discloses a compound related to inhibiting the activity of an IRAK4 kinase. It includes a pharmaceutical composition, methods for inhibiting IRAK4 kinase activity, and applications for treating or preventing IRAK4 kinase-mediated diseases in mammals, especially humans. The compound has a structural formula I.
Career Highlights
Jiangcheng Xu is associated with Beijing Hanmi Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in kinase inhibition has positioned him as a key player in drug development.
Collaborations
He has collaborated with notable colleagues, including Qinguan Cai and Mi Young Cha, contributing to a dynamic research environment.
Conclusion
Jiangcheng Xu's work in developing IRAK4 inhibitors showcases his commitment to advancing medical science. His contributions are vital for the future of therapeutic interventions.